Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...

Generic dapagliflozin is indicated for adults with type 2 diabetes and to reduce heart failure hospitalization risk in adults with T2D and established cardiovascular disease. The Food and Drug ...

The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...

A new report dubbed "BrowserGate" warns that Microsoft's LinkedIn is using hidden JavaScript scripts on its website to scan visitors' browsers for installed extensions and collect device data.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. LinkedIn has built its reputation as the world's most trusted professional network, with ...

March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...

Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...

At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the ...

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

You know LinkedIn language when it pops up. What could be simple career updates are turned into lengthy announcements, all with a similar structure: short/punchy sentences, an emphasis on personal ...